Onderneming Orchard Therapeutics plc
Aandelen
ORTX
US68570P2002
Farmaceutische producten
Vakgebied
Aantal werknemers: 166
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Bobby Gaspar
CEO | Chief Executive Officer | 60 | 01-01-15 |
Frank Thomas
PSD | President | 54 | 01-01-18 |
Leslie Meltzer
CTO | Chief Tech/Sci/R&D Officer | - | 01-06-18 |
Nicoletta Loggia
CTO | Chief Tech/Sci/R&D Officer | - | 09-09-21 |
Fulvio Mavilio
CTO | Chief Tech/Sci/R&D Officer | - | 01-01-22 |
Renee T. Leck
IRC | Investor Relations Contact | - | - |
Christopher York
SEC | Corporate Secretary | - | - |
Braden Parker
PRN | Corporate Officer/Principal | - | - |
John Cerio
HRO | Human Resources Officer | - | - |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Abdul Mullick
BRD | Director/Board Member | - | 24/01 |
Yasuo Fujii
BRD | Director/Board Member | - | 24/01 |
60 | - | ||
Director/Board Member | 62 | 24/01 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 126 572 749 | 81 786 701 ( 64,62 %) | 0 | 64,62 % |
Bedrijfsgegevens
Orchard Therapeutics Plc
245 Hammersmith Road 3rd Floor
W6 8PW, London
+44 20 3 808 8286
http://www.orchard-tx.comSector
Vaira. 1 jan. | Kapi. | |
---|---|---|
+33,46% | 701 mld. | |
+26,24% | 570 mld. | |
+0,93% | 381 mld. | |
+21,03% | 334 mld. | |
+17,51% | 322 mld. | |
+0,74% | 209 mld. | |
+2,95% | 212 mld. | |
-6,05% | 205 mld. | |
-3,61% | 157 mld. |